Mundipharma EDO GmbH have entered into an agreement for the development and testing of a DRP ™ biomarker for Mundipharma EDO’s lead compound EDO-S101

Medical Prognosis Institute A/S (MPI.CO) (Denmark and Phoenix, AZ, USA) announced today that MPI and Mundipharma EDO GmbH have entered into an agreement for the development and testing of a DRP™ biomarker for Mundipharma EDO’s lead compound EDO-S101 for the treatment of cancer.EDO-S101 is a first in class fusion molecule that combines two drugs' mechanism of action in the cancer cell in order to increase the effect of treatment.MPI's specific DRP™ multiple biomarker for EDO-S101 is to identify those patients who have the highest likelihood of response to the combination of bendamustine and vorinostat. Thereby the response rate will increase and time and resources spent will decrease. "We are excited at the prospect of our partner Mundipharma EDO moving into Phase I with a DRP™ biomarker developed by MPI A/S,"says adjunct professor Peter Buhl Jensen, M.D., Ph.d., CEO at MPI.“This is precisely where MPI's DRP™ makes a difference, due to the fact that our technology can be used for all cancer diseases and for most anti cancer drugs on the market or under development,” addsadjunct professor Peter Buhl Jensen, M.D., Ph.d., CEO at MPI. Mundipharma EDO CEO Dr. Thomas Mehrling says"We look forward to seeing a validation of MPI's DRP biomarker in our clinical trials". About the Anti Cancer drug candidate EDO-S101EDO-S101 is a first in class fusion molecule that combines the DNA damaging effect...
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news

Related Links:

Authors: Wierzba W, Śliwczynski A, Karnafel W, Dziemidok P, Pinkas J Abstract Introduction: Many epidemiological studies show a correlation between the risk of cancer and type 2 diabetes mellitus in various populations. Material and methods: The material was obtained from the database of the National Health Fund. This publication presents a comparison of the incidence of new malignancies in rural and urban populations of diabetic patients in Poland based on the database of the National Health Fund for the period between 1.05.2008 and 30.09.2014. Results: Comparison of the mean incidence of selected maligna...
Source: Archives of Medical Science - Category: General Medicine Tags: Arch Med Sci Source Type: research
In this study, we aimed to identify the profiles of PRCC expression in Korean NSCLC patients and to elucidate the role of PRCC overexpression on lung tumorigenesis. MATERIALS AND METHODS: We performed immunohistochemistry analysis with a tissue array containing 161 primary NSCLCs. Small interfering RNA targeting PRCC (siPRCC) was transfected into two lung cancer cell lines (NCI-H358 and A549), after which tumor growth, migration, and invasion were observed. Expressions of cell proliferation-, cell cycle-, and metastasis-related molecules were examined by Western blot analysis. We also explored the in vivo effect of PR...
Source: Yonsei Medical Journal - Category: Universities & Medical Training Authors: Tags: Yonsei Med J Source Type: research
Authors: Tamura K, Horikawa M, Sato S, Miyake H, Setou M Abstract Clear cell renal cell carcinoma (ccRCC) often results in recurrence or metastasis, and there are only a few clinically effective biomarkers for early diagnosis and personalized therapy. Metabolic changes have been widely studied using mass spectrometry (MS) of tissue lysates to identify novel biomarkers. Our objective was to identify lipid biomarkers that can predict disease progression in ccRCC by a tissue-based approach. We retrospectively investigated lipid molecules in cancerous tissues and normal renal cortex tissues obtained from patients with ...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
In conclusion, CEP55 was increased in ccRCC samples, and may be considered a potential diagnostic and prognostic biomarker for ccRCC. PMID: 30896867 [PubMed - as supplied by publisher]
Source: Molecular Medicine Reports - Category: Molecular Biology Tags: Mol Med Rep Source Type: research
t Miski Seven known sesquiterpene coumarins and a new sesquiterpene coumarin, anatolicin (8), were isolated from the dichloromethane extract of the roots of Heptaptera anatolica. Structures of these compounds were elucidated based on their spectral properties. While some of these sesquiterpene coumarins showed modest cytotoxic activity against COLO205, KM12, A498, UO31, and TC32 cancer cell lines, selective cytotoxicity of anatolicin (8) and 14′-acetoxybadrakemin (7) were observed at nanomolar level against the UO31 kidney cancer cell line.
Source: Molecules - Category: Chemistry Authors: Tags: Article Source Type: research
Authors: Liviu Preda A, Galieta Mincă D Abstract Rationale: In recent years, the cost of several treatment options for renal cancer have been supported by the Romanian healthcare system for both first- and second-line therapies. First-line alternatives through real-life efficacy and amplitude of adverse reactions may influence the efficacy and costs of patients treated with second-line treatment. Objective: Estimation of the cost-effectiveness and cost-benefit ratio for first-line treatment alternatives: Sunitinib and Pazopanib from the payer's perspective in the Romanian healthcare system. Methods and Results: We...
Source: Journal of Medicine and Life - Category: General Medicine Tags: J Med Life Source Type: research
Clinical trials are research studies that test a new drug or therapy in patients who have a disease. These studies are classified as phase I, II, or III depending on their purpose. Phase I: These initial, small studies test promising new drugs that effectively kill cancer cells in laboratory experiments. The goal is to understand the safe dose and capture early evidence of benefit. Phase I trials may be open to patients with any type of cancer, or only certain types of cancers more likely to respond to specific drugs. Generally, fewer than 50 patients are enrolled. Phase II: Once a phase I trial identifies a saf...
Source: Harvard Health Blog - Category: Consumer Health News Authors: Tags: Breast Cancer Health Treatments Source Type: blogs
This study also compared prognostic models containing CRP kinetics and neutrophil-to-lymphocyte ratio (NLR) kinetics. Materials and Methods: A consecutive cohort of 94 patients with mRCC who were treated with sunitinib was retrospectively included from Fudan University Shanghai Cancer Center. According to dynamic changes in CRP and the NLR, patients were divided into three groups for analysis of CRP and NLR kinetics. The associations between survival and potential prognostic factors were assessed. The incremental value of prognostication was evaluated. Results: A significant difference (P
Source: International Braz J Urol - Category: Urology & Nephrology Source Type: research
We examined expression patterns of SGLTs in tumor tissues together with conventional pathological variables to determine prognostic significance in patients with renal cell carcinoma (RCC). Materials and Methods: Nephrectomy specimens were obtained from 68 patients. GLUT - 1, - 2 and SGLT - 1, - 2 expression in tumor and adjacent normal tissues were analyzed by immunohistochemical staining, and intensity was quantified using an image analyzer. Results: The four glucose transporters evaluated were broadly distributed in tumor tissues as well as throughout the normal parenchyma. There was no significant correlation between t...
Source: International Braz J Urol - Category: Urology & Nephrology Source Type: research
Conclusion: This study can be taken as a small step toward making the registry of patients with urogenital tumors providing valuable information regarding the frequency, clinical presentation, and histological spectrum. Large population-based studies for a longer duration of time across both males and females are needed in the ever-changing trends of urogenital tumors.
Source: Journal of Cancer Research and Therapeutics - Category: Cancer & Oncology Authors: Source Type: research
More News: Cancer | Cancer & Oncology | Clinical Trials | Denmark Health | Genetics | Kidney Cancer | Statistics | Treanda | Urology & Nephrology